Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 2, 2004
- JPMA to Provide Technology, Assistance in Asia in FY2004
August 2, 2004
- Therapeutic Category of 380 Generics Clarified
August 2, 2004
- GE Makers to Distinguish Themselves from Competitors
August 2, 2004
- Meet the Leaders (35)
August 2, 2004
- WORLD NEWS IN BRIEF
August 2, 2004
- MEDICAL DEVICE NEWS IN BRIEF
August 2, 2004
- 1st 3Qtrs Business Results
August 2, 2004
- DIAGNOSTIC NEWS IN BRIEF
August 2, 2004
- 1st Qtr Business Results
August 2, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
August 2, 2004
- OTC NEWS IN BRIEF
August 2, 2004
- Ban Lifted on Sale of 371 OTC Drugs by General Retailers
August 2, 2004
- SSP to Concentrate on Self-medication
August 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 2, 2004
- BULLETIN
August 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 26, 2004
- Kyoso Mirai Group Considering Holding Company System: Mr Hamada of Toho
July 26, 2004
- EPMA to Consider Affiliation with IGPA
July 26, 2004
- BUSINESS NEWS IN BRIEF
July 26, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…